Compared with conventional anti-EGFR monoclonal antibodies (such as cetuximab), EGFR/CD3 bispecific antibodies not only block EGFR-mediated tumor proliferation signaling but also actively recruit T cells to exert cytotoxic effects. The gene discussed is EGFR; the disease is neoplasm.